Literature DB >> 21507830

A clinician's guide to perioperative bridging for patients on oral anticoagulation.

Michelle T Martin1, Ann M Kuchta, Edith A Nutescu.   

Abstract

Updates in recent clinical guidelines have led to a change in the management of perioperative anticoagulation for patients on oral anticoagulant therapy. No standardized bridging consensus exists in the literature. The necessity for bridging therapy is determined based on careful consideration of the thrombosis risk versus the bleeding risk of the procedure. Risk stratification will aid the decision to bridge or not to bridge. Patients are bridged with agents with appropriate kinetics to allow for their elimination prior to the time of the procedure in order to decrease the risk of hemorrhage during invasive procedures. This intent of this article is to discuss perioperative bridging therapy and provide a practical guide for the clinician.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21507830     DOI: 10.1177/0897190010363276

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  3 in total

1.  Results of surgery in general surgical patients receiving warfarin: retrospective analysis of 61 patients.

Authors:  Sedat Belli; Huseyin Ozgur Aytac; Hakan Yabanoglu; Erdal Karagulle; Alper Parlakgumus; Tarik Zafer Nursal; Sedat Yildirim
Journal:  Int Surg       Date:  2015-02

2.  The minimally invasive approach is associated with reduced perioperative thromboembolic and bleeding complications for patients receiving preoperative chronic oral anticoagulant therapy who undergo colorectal surgery.

Authors:  Barlas Sulu; Erman Aytac; Luca Stocchi; Jon D Vogel; Ravi P Kiran
Journal:  Surg Endosc       Date:  2012-10-24       Impact factor: 4.584

3.  Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation.

Authors:  Karen Smoyer-Tomic; Kimberly Siu; David R Walker; Barbara H Johnson; David M Smith; Stephen Sander; Alpesh Amin
Journal:  Am J Cardiovasc Drugs       Date:  2012-12-01       Impact factor: 3.571

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.